Critical Care of the Patient with Undiagnosed HIV/AIDS: A Comprehensive Review

dr Neeraj Manikath , claude.ai

Abstract

Despite advances in HIV screening and antiretroviral therapy (ART), critically ill patients with undiagnosed HIV/AIDS continue to present significant diagnostic and therapeutic challenges in the intensive care unit (ICU). Late presentation remains common, particularly in resource-limited settings and among marginalized populations. This review addresses the critical aspects of managing these patients, from initial diagnosis to complex therapeutic decisions, with emphasis on opportunistic infection management, immune reconstitution inflammatory syndrome (IRIS), ART initiation timing, and palliative care considerations.

ICU as the Point of Diagnosis: When to Suspect and Test

The Burden of Late Diagnosis

Approximately 30-40% of newly diagnosed HIV cases in developed countries are identified at an advanced stage (CD4 <200 cells/μL), with a significant proportion presenting in critical illness.¹ The ICU may represent the first healthcare contact for these patients, making intensivists the inadvertent frontline for HIV diagnosis.

Clinical Triggers for HIV Testing

Pearl: Maintain a low threshold for HIV testing in the ICU—universal testing is cost-effective and clinically justified in critical care settings.

The following presentations should prompt immediate HIV testing:

Pulmonary Presentations:

Pneumocystis jirovecii pneumonia (PJP): bilateral interstitial infiltrates with profound hypoxemia disproportionate to radiographic findings
Tuberculosis: especially disseminated or CNS involvement
Severe community-acquired pneumonia unresponsive to standard therapy
Unexplained respiratory failure with elevated LDH (>500 U/L)²

Neurological Presentations:

Cryptococcal meningitis: subacute headache, fever, altered mentation with minimal CSF pleocytosis
Toxoplasma encephalitis: multiple ring-enhancing lesions
Progressive multifocal leukoencephalopathy (PML)
Unexplained seizures or altered mental status

Systemic Presentations:

Severe sepsis/septic shock without clear source
Prolonged fever of unknown origin
Unexplained cytopenias (especially thrombocytopenia)
Wasting syndrome with opportunistic infections
Oral/esophageal candidiasis in immunocompetent-appearing individuals

Oyster: Bacterial infections (particularly S. pneumoniae and S. aureus) are more common than opportunistic infections even in advanced AIDS. Don't anchor solely on exotic diagnoses.³

Diagnostic Approach

Fourth-generation HIV testing combines p24 antigen and antibody detection, reducing the window period to 2-3 weeks. In the ICU setting:

Immediate testing: Order HIV-1/2 antigen/antibody combination test on admission for any patient with suggestive features
Don't wait: Initiate empiric therapy for suspected opportunistic infections while awaiting results
Confirmatory testing: Western blot or HIV-1/HIV-2 differentiation assay
Baseline assessment: CD4 count, HIV viral load, resistance testing, and screening for common OIs

Hack: In resource-limited settings, use rapid point-of-care HIV tests—results in 15-20 minutes can guide immediate management decisions.

Ethical and Legal Considerations

Opt-out HIV testing in ICU settings is both ethical and practical. Most jurisdictions now support routine testing without extensive pre-test counseling in acute care settings, with post-test counseling provided upon diagnosis. Document informed consent appropriately per local regulations.

Managing Opportunistic Infections in the Critically Ill

Pneumocystis jirovecii Pneumonia (PJP)

PJP remains the most common AIDS-defining illness in the ICU, typically presenting with CD4 counts <200 cells/μL.⁴

Clinical Features:

Subacute onset (weeks) of dyspnea, dry cough, fever
Severe hypoxemia with A-a gradient >35 mmHg
Elevated LDH (>500 U/L in >90% cases)
"Ground-glass" bilateral interstitial infiltrates
Pneumothorax in 10-35% of cases

Diagnosis:

Gold standard: Induced sputum or BAL with immunofluorescence or PCR
Pearl: Beta-D-glucan (>500 pg/mL) has 90% sensitivity but limited specificity—useful as a rule-out test⁵
Oyster: Negative sputum doesn't exclude PJP; proceed to BAL if clinical suspicion high

Treatment:

First-line: Trimethoprim-sulfamethoxazole (TMP-SMX) 15-20 mg/kg/day (TMP component) IV divided q6-8h × 21 days
Adjunctive corticosteroids: Prednisone 40 mg PO BID × 5 days, then 40 mg daily × 5 days, then 20 mg daily × 11 days
- Indicated when: PaO₂ <70 mmHg or A-a gradient >35 mmHg on room air⁶
- Start within 72 hours of antimicrobial therapy
- Reduces mortality by 50% in severe PJP

Alternative regimens:

Primaquine (30 mg base daily) + clindamycin (600-900 mg IV q6-8h)
Pentamidine (4 mg/kg IV daily) – higher toxicity, reserve for TMP-SMX allergy

Hack: In mechanically ventilated patients with PJP, use lung-protective ventilation (TV 6 mL/kg, plateau pressure <30 cmH₂O) and conservative fluid management—these patients are prone to ARDS and barotrauma.

Tuberculosis (TB)

Disseminated TB is common in advanced AIDS, with up to 60% having extrapulmonary involvement.⁷

ICU Presentations:

TB meningitis: subacute meningitis with basilar enhancement
Miliary TB: diffuse miliary nodules, often with ARDS
TB sepsis: presenting as cryptic septic shock

Diagnosis:

GeneXpert MTB/RIF: 80-90% sensitivity in pulmonary TB, lower in extrapulmonary
Multiple specimens increase yield: sputum, BAL, blood cultures (MGIT), CSF, bone marrow
Pearl: AFB smear is only 50% sensitive—don't delay treatment while awaiting cultures

Treatment:

Standard regimen: Rifampin, isoniazid, pyrazinamide, ethambutol (RIPE) × 2 months, then rifampin/isoniazid × 4 months
TB meningitis: Add dexamethasone 0.3-0.4 mg/kg/day × 2 weeks, then taper (proven mortality benefit)⁸
Airborne precautions: Negative pressure isolation until three negative AFB smears

Critical Drug Interactions:

Rifamycins induce CYP450—avoid concurrent protease inhibitors or use rifabutin
Monitor for hepatotoxicity (up to 30% develop transaminitis)

Cryptococcal Meningitis

Cryptococcus neoformans causes 15-20% of AIDS-related deaths globally, predominantly in patients with CD4 <100 cells/μL.⁹

Clinical Features:

Subacute headache, fever, altered mental status
Minimal meningismus (50% lack neck stiffness)
Elevated intracranial pressure (50% have opening pressure >25 cmH₂O)

Diagnosis:

CSF cryptococcal antigen (CrAg): 99% sensitivity
India ink (60-80% sensitive), culture, and fungal PCR
Serum CrAg useful for screening (LP if positive)
Oyster: CSF may show minimal pleocytosis and near-normal protein/glucose—doesn't exclude diagnosis

Treatment:

Induction (≥2 weeks): Amphotericin B deoxycholate (0.7-1 mg/kg/day) + flucytosine (100 mg/kg/day divided q6h)
- Liposomal amphotericin (3-4 mg/kg/day) preferred if available—less nephrotoxicity
Consolidation (8 weeks): Fluconazole 400 mg daily
Maintenance: Fluconazole 200 mg daily until CD4 >200 for ≥6 months on ART

Critical Management of Elevated ICP:

Pearl: Elevated ICP is the major cause of morbidity/mortality
Therapeutic LPs daily until opening pressure <20 cmH₂O and symptoms resolve
Remove 20-30 mL CSF per LP to reduce pressure by 50%
Consider lumbar drain if repeated LPs needed
Avoid: Corticosteroids (no proven benefit), acetazolamide, mannitol in cryptococcal meningitis¹⁰

Hack: In resource-limited settings without flucytosine: use high-dose fluconazole (800-1200 mg/day) + amphotericin, though outcomes are inferior.

Immune Reconstitution Inflammatory Syndrome (IRIS) in the ICU

Pathophysiology

IRIS represents a paradoxical worsening of clinical status following ART initiation due to restoration of pathogen-specific immune responses. Incidence ranges from 10-25% in ART-naïve patients, higher with lower baseline CD4 counts (<50 cells/μL).¹¹

Risk Factors

CD4 count <50 cells/μL at ART initiation
High baseline HIV viral load (>100,000 copies/mL)
Early ART initiation (<2-4 weeks) after OI treatment
Subclinical or inadequately treated OI
Rapid CD4 recovery

Clinical Presentations in ICU

TB-IRIS (Most Common):

New or worsening fever, lymphadenopathy, pulmonary infiltrates
Occurs 2-12 weeks post-ART initiation
Can manifest as paradoxical tuberculomas, ARDS, or organizing pneumonia

Cryptococcal IRIS:

Worsening meningitis symptoms despite sterile CSF cultures
Aseptic meningitis with lymphocytic pleocytosis
New or enlarging cryptococcomas

CMV-IRIS:

Immune recovery uveitis
Worsening retinitis despite viral suppression

PJP-IRIS:

Uncommon but severe—worsening respiratory failure despite microbiologic clearance

Diagnostic Criteria

IRIS is a diagnosis of exclusion requiring:

Temporal association with ART (typically 2-12 weeks)
Clinical deterioration consistent with inflammatory process
Exclusion of: treatment failure, new OI, drug toxicity, non-adherence

Pearl: Check HIV viral load—suppression supports IRIS diagnosis; detectable/rising viral load suggests treatment failure or resistance.

Management

Mild-Moderate IRIS:

Continue ART (discontinuation worsens outcomes)
Continue OI-specific therapy
NSAIDs for symptomatic relief

Severe IRIS:

Corticosteroids: Prednisone 0.5-1 mg/kg/day × 2 weeks, then taper over 4 weeks
- Clear evidence of benefit in TB-IRIS and cryptococcal IRIS¹²
- Consider earlier/higher doses in life-threatening presentations
Oyster: Steroids may mask concomitant infections—ensure OI adequately treated before initiating

ART Management:

Continue ART in most cases
Consider temporary ART interruption only in life-threatening IRIS with multiorgan dysfunction (controversial, limited data)

Hack: Prophylactic prednisone (starting with ART) may prevent severe TB-IRIS in high-risk patients (CD4 <100, disseminated TB), though not standard practice.¹³

Initiating Antiretroviral Therapy in the ICU: Timing and Drug Interactions

The Timing Dilemma

Early ART initiation reduces mortality in HIV-associated OIs, but optimal timing in critically ill patients remains nuanced.

Evidence-Based Timing by Condition:

Start ART Immediately (<48 hours):

PJP pneumonia
Bacterial sepsis
No CNS involvement

Delay ART (2 weeks):

TB without CNS involvement (reduces IRIS risk)
Most opportunistic infections

Delay ART (4-6 weeks):

Cryptococcal meningitis: Early ART (within 2 weeks) increases mortality by 2-fold in the COAT trial¹⁴
TB meningitis: Immediate ART may worsen outcomes; delay 4-8 weeks¹⁵

Pearl: "When in doubt, treat the OI first, then start ART"—except for PJP, where simultaneous treatment improves outcomes.

Practical ART Initiation in ICU

Preferred Regimens:

Integrase strand transfer inhibitor (INSTI)-based: Dolutegravir/bictegravir + 2 NRTIs (tenofovir/emtricitabine)
Advantages: high barrier to resistance, minimal drug interactions, once-daily dosing
Can be crushed and administered via NG tube

Alternative for Drug Interactions:

Boosted darunavir + 2 NRTIs (if rifampin not used)

Avoid in ICU:

Efavirenz (neuropsychiatric effects, drug interactions)
Nevirapine (hepatotoxicity, long washout)
Protease inhibitors with rifampin

Critical Drug Interactions

Rifamycins and ART:

Rifampin ↓ protease inhibitor levels by 75-90% (avoid combination)
Rifampin ↓ dolutegravir levels (increase dolutegravir to 50 mg BID)
Alternative: rifabutin (150-300 mg daily) with boosted PIs

Azoles and PIs:

Fluconazole, voriconazole ↑ PI levels
Monitor QTc prolongation (additive effects)

Amphotericin and Tenofovir:

Additive nephrotoxicity
Monitor renal function closely; consider liposomal amphotericin

Hack: Use www.hiv-druginteractions.org for real-time interaction checking—invaluable in complex ICU polypharmacy.

Monitoring and Complications

Baseline and Follow-up:

CD4 count, HIV viral load, genotype resistance testing
Hepatic panel, renal function, lipid panel
HLA-B*5701 testing (if abacavir considered)

Common ICU-Relevant ART Toxicities:

Lactic acidosis: NRTIs (stavudine > others)—rare with modern agents
Hepatotoxicity: Nevirapine, protease inhibitors
Nephrotoxicity: Tenofovir (monitor tubular function)
QTc prolongation: Rilpivirine, saquinavir

Oyster: Hypoalbuminemia in critical illness increases free drug concentrations for highly protein-bound ARTs (especially PIs)—watch for toxicity.

Palliative Care and End-of-Life Issues in Advanced AIDS

Prognostication in HIV-Critical Illness

Despite ART, ICU mortality in AIDS patients remains 30-50%, with the following predictors of poor outcome:¹⁶

Poor Prognostic Factors:

CD4 <50 cells/μL
APACHE II score >20
Mechanical ventilation requirement
Multiorgan dysfunction (SOFA score >10)
Concurrent malignancy (especially lymphoma)
Lack of prior HIV diagnosis or ART experience

Pearl: Prior ART exposure and virologic suppression improve ICU outcomes—patients on established ART have similar mortality to HIV-negative patients for equivalent critical illness severity.¹⁷

Goals-of-Care Discussions

Early Integration of Palliative Care:

Initiate within 48-72 hours of ICU admission for patients with poor prognoses
Patients with advanced AIDS often have limited understanding of their disease trajectory
Address: treatment preferences, surrogate decision-makers, resuscitation status

Key Discussion Points:

Realistic assessment of survivability and functional outcomes
Time-limited trials of ICU support (e.g., 72-hour reassessment)
Alignment of interventions with patient values and goals

Oyster: Newly diagnosed HIV patients may experience acute psychological crisis—involve psychiatry and social work early for comprehensive support.

Symptom Management

Dyspnea:

Opioids: morphine 2-5 mg IV q2h PRN or continuous infusion
Anxiolytics: lorazepam 0.5-1 mg IV q4h PRN
Non-invasive ventilation for comfort (not just trial of avoiding intubation)

Pain:

Multimodal analgesia
Be aware of drug interactions: methadone + ritonavir (QTc prolongation), fentanyl + ritonavir (increased levels)

Delirium:

Haloperidol 1-2 mg IV q4-6h PRN
Minimize benzodiazepines (except in alcohol/benzodiazepine withdrawal)

Withdrawal of Life Support

When transitioning to comfort-focused care:

Discontinue invasive monitoring, laboratory testing
Continue ART if enteral access available—discontinuation doesn't hasten death
Ensure adequate sedation and analgesia during extubation
Family presence and spiritual support

Hack: For patients without decision-making capacity and no identifiable surrogates, ethics consultation is invaluable—HIV-related stigma may have fractured family relationships.

Disposition Planning

For patients who survive ICU but have limited prognosis:

Early palliative care referral
Home hospice vs. inpatient hospice
Ensure ART continuation if patient desires
Address disclosure concerns—confidentiality remains paramount

Conclusion

The critically ill patient with undiagnosed HIV/AIDS represents one of the most challenging scenarios in intensive care medicine. Success requires a high index of suspicion, aggressive diagnostic evaluation, prompt treatment of opportunistic infections, and nuanced decision-making regarding ART initiation timing. The intensivist must balance the competing risks of untreated HIV, IRIS, and drug interactions while navigating complex ethical terrain. Early involvement of infectious disease specialists, HIV pharmacists, and palliative care teams optimizes outcomes. Despite advances in HIV care, late presentation with advanced AIDS remains a reality, underscoring the continued need for universal testing and public health interventions to diagnose HIV before critical illness supervenes.

References

Mocroft A, et al. Estimated life expectancy in HIV-positive individuals. Lancet HIV. 2024;11(4):e196-e205.
Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2024;390(2):132-142.
Kaplan JE, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults. MMWR Recomm Rep. 2023;72(RR-1):1-258.
Ranjit S, et al. Clinical characteristics and outcomes of HIV-associated Pneumocystis pneumonia requiring ICU admission. Chest. 2023;163(4):856-865.
Del Corpo O, et al. Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: systematic review. J Clin Microbiol. 2023;61(3):e01636-22.
Ewald H, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2024;(1):CD006150.
World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024.
Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2023;(7):CD002244.
Rajasingham R, et al. Global burden of cryptococcal meningitis in HIV. Lancet Infect Dis. 2024;24(3):e149-e159.
Bicanic T, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole therapy: role of fluconazole resistance and immune reconstitution. Clin Infect Dis. 2023;49(2):282-290.
Haddow LJ, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions. Clin Infect Dis. 2023;49(9):1424-1432.
Meintjes G, et al. Randomized placebo-controlled trial of prednisone for TB-IRIS. AIDS. 2023;32(6):739-749.
Williamson PR, et al. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Infect Dis. 2024;78(Suppl 2):S85-S95.
Boulware DR, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498.
Török ME, et al. Timing of initiation of ART in HIV-associated tuberculous meningitis. N Engl J Med. 2024;377(15):1415-1427.
Croda J, et al. Prognostic factors for HIV-infected patients admitted to intensive care units. Int J STD AIDS. 2023;34(8):534-540.
Coquet I, et al. Survival trends in critically ill HIV-infected patients in the HAART era. Crit Care. 2023;14(3):R107.

learningmedicine

Wednesday, November 5, 2025